Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

Juan Ruiz-Bañobre^{1

2

3

4}, Ajay Goel^{5

6}

Affiliations

¹ Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela (SERGAS), University of Santiago de Compostela (USC), A Coruña, Spain.
² Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), A Coruña, Spain.
³ Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), A Coruña, Spain.
⁴ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
⁵ Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, California.
⁶ City of Hope Comprehensive Cancer Center, Duarte, California.

PMID: 37079293
DOI: 10.1001/jamaoncol.2023.0329

Editorial

Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

Juan Ruiz-Bañobre et al. JAMA Oncol. 2023.

. 2023 Jun 1;9(6):763-764.

doi: 10.1001/jamaoncol.2023.0329.

Authors

Juan Ruiz-Bañobre^{1

2

3

4}, Ajay Goel^{5

6}

Affiliations

¹ Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela (SERGAS), University of Santiago de Compostela (USC), A Coruña, Spain.
² Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), A Coruña, Spain.
³ Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), A Coruña, Spain.
⁴ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
⁵ Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, California.
⁶ City of Hope Comprehensive Cancer Center, Duarte, California.

PMID: 37079293
DOI: 10.1001/jamaoncol.2023.0329

No abstract available

PubMed Disclaimer

Comment on

Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
Mo S, Ye L, Wang D, Han L, Zhou S, Wang H, Dai W, Wang Y, Luo W, Wang R, Xu Y, Cai S, Liu R, Wang Z, Cai G. Mo S, et al. JAMA Oncol. 2023 Jun 1;9(6):770-778. doi: 10.1001/jamaoncol.2023.0425. JAMA Oncol. 2023. PMID: 37079312 Free PMC article.

Cited by

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies.
Kiran NS, Yashaswini C, Maheshwari R, Bhattacharya S, Prajapati BG. Kiran NS, et al. ACS Pharmacol Transl Sci. 2024 Mar 19;7(4):967-990. doi: 10.1021/acsptsci.4c00008. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633600 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

U01 CA187956/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

Affiliations

Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical